Bill DeGrado, Ph.D., is a Professor in the Department of Pharmaceutical Chemistry at UCSF, where he is also a member of the Cardiovascular Research Institute. Dr. DeGrado’s work focuses on the design of small molecule drugs, peptides, proteins and peptide mimetics. Before joining UCSF in 2011, he was a member of DuPont Central Research and DuPont Merck Pharmaceutical Company and the George W. Raiziss Professor in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. DeGrado is a member of the National Academy of Science, the National Academy of Inventors, the American Academy of Arts and Sciences, and a fellow of the American Association for the Advancement of Science. He is also a past President of the Protein Society and was the scientific founder of PolyMedix, which discovered brilacidin. Brilacidin, currently licensed to Cellceutix, is now in Phase 3 clinical trials for drug-resistant Staphylococcal aureus infections. Some of Dr. DeGrado’s research interests include de novo design of proteins and peptides; peptide mimetics; structure/function of membrane proteins, including integrins and viral ion channels; small molecule drug design; and bioinorganic chemistry.
Dr. DeGrado graduated from Kalamazoo College and holds a Ph.D. in organic chemistry from the University of Chicago. He joined the DuPont Central Research without an intervening postdoctoral position.